MCID: HPT003
MIFTS: 63

Hepatitis a

Categories: Infectious diseases, Rare diseases, Liver diseases, Gastrointestinal diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 72 40 41 14 69
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12549
MeSH 41 D006506
NCIt 46 C3096
SNOMED-CT 64 154347003 40468003
ICD10 32 B15.0 B15.9
UMLS 69 C0019159

Summaries for Hepatitis a

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and alcoholic hepatitis, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Aluminum hydroxide and Aluminum sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes, and related phenotype is neoplasm.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted_by ingestion of contaminated food or water, or transmitted_by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 72 Hepatitis A is an infectious disease of the liver caused by the hepatitis A virus (HAV). Many cases have... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.5 AFP F2 GPT HAVCR1 HAVCR2 IFNA2
2 alcoholic hepatitis 30.1 ALB F2 GPT TNF
3 acute liver failure 29.9 ALB F2 GPT
4 cholecystitis 29.8 ALB F2 GPT
5 hepatitis c 29.8 AFP GPT IFNA2 TNF
6 hepatitis e 29.7 ALB F2 GPT TNF
7 bilirubin metabolic disorder 29.5 ALB F2 GPT
8 liver disease 29.4 AFP ALB F2 F3 GPT SERPINA1
9 hepatic coma 29.1 ALB F2 GPT
10 vasculitis 29.1 IFNA2 SERPINA1 TNF
11 hepatitis d 29.0 F2 GPT IFNA2
12 cholangitis 29.0 ALB F2 GPT TNF
13 scrub typhus 29.0 F3 GPT TNF
14 viral hepatitis 29.0 AFP ALB F2 GPT IFNA2 SERPINA1
15 pyoderma 28.9 F3 IFNA2 TNF
16 primary biliary cirrhosis 28.8 ALB F2 GPT
17 hepatic encephalopathy 28.8 ALB F2 GPT TNF
18 portal hypertension 28.8 ALB F2 GPT TNF
19 purpura 28.7 F2 F3 SERPINC1 TNF
20 malaria 28.6 ALB F3 HAVCR2 TGFB1 TNF
21 hepatitis b 28.6 AFP ALB F2 GPT IFNA2 TGFB1
22 dengue hemorrhagic fever 28.5 ALB F2 F3 TNF
23 thrombophilia due to thrombin defect 28.5 F2 F3 SERPINC1
24 thrombosis 28.4 F2 F3 SERPINC1
25 hepatocellular carcinoma 28.2 AFP ALB F2 SERPINA1 TGFB1
26 systemic lupus erythematosus 28.0 ALB F2 F3 TGFB1 TNF
27 hemorrhagic fever 27.5 ALB F2 F3 GPT SERPINC1 TNF
28 liver cirrhosis 27.1 AFP ALB F2 GPT SERPINA1 SERPINC1
29 fatty liver disease 10.7
30 hepatoid adenocarcinoma 10.5 AFP ALB
31 adult dermatomyositis 10.4 GPT TNF
32 opisthorchiasis 10.4 AFP GPT
33 antipyrine metabolism 10.4 ALB F2
34 non-a-e hepatitis 10.4 ALB F2
35 beryllium disease 10.4 TGFB1 TNF
36 hepatoportal sclerosis 10.4 F2 GPT
37 mucinous cystadenofibroma 10.4 AFP SERPINA1
38 polyembryoma 10.4 AFP SERPINA1
39 abdominal tuberculosis 10.4 ALB F2
40 marburg hemorrhagic fever 10.3 F2 TNF
41 adult xanthogranuloma 10.3 HAVCR1 SERPINA1
42 endometrial small cell carcinoma 10.3 AFP F2
43 laryngitis 10.3 TGFB1 TNF
44 vitamin k deficiency hemorrhagic disease 10.3 AFP F2
45 peyronie disease 10.3 IFNA2 TGFB1
46 protein-energy malnutrition 10.3 ALB GPT TNF
47 constrictive pericarditis 10.3 ALB SERPINA1
48 hemangioma of liver 10.3 F2 IFNA2
49 penile disease 10.3 IFNA2 TGFB1
50 clonorchiasis 10.3 TGFB1 TNF

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

UMLS symptoms related to Hepatitis a:


gastrointestinal gas, pruritus, nausea and vomiting, icterus, heartburn, fever, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Hepatitis a:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 F3 HSPA5 TGFB1 TNF AFP ALB

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 777)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Aluminum sulfate Approved Phase 4,Phase 3,Phase 1,Phase 2 10043-01-3
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
6
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
7
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
8
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
9
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
10
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
11
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
12
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
13
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5381226 5458213
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
16
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
17
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
18
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
19
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
22
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
23
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
24
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
25
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
28
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
29
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
30
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
31
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1256388-51-8 67505836
32
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1190307-88-0 45375808
33
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2 8008-53-5
34
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
35
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
36
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
37
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128-13-2 31401
38
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
39
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
40
Insulin Glargine Approved Phase 4 160337-95-1
41
Insulin-glulisine Approved Phase 4 207748-29-6
42
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
43
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
44
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
45
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
46
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
47
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
48
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
49
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
50 Simethicone Approved Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 4143)

# Name Status NCT ID Phase Drugs
1 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
2 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
5 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
6 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
9 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
10 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
11 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
12 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
13 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
14 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
15 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
16 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
17 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
18 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
19 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
20 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
21 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
22 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
23 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
24 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
25 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
26 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
27 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
28 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
29 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
30 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
31 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
32 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
33 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
34 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
35 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
36 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
37 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
38 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
39 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
40 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
41 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
42 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
43 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
44 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
45 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
46 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
47 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
48 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
49 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
50 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

18
Liver

MalaCards organs/tissues related to Hepatitis a:

38
Liver, Testes, Kidney, Bone, T Cells, Bone Marrow, B Cells

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 952)
# Title Authors Year
1
Pathogenicity of duck hepatitis A virus type 3 and innate immune responses of the ducklings to virulent DHAV-3. ( 29407574 )
2018
2
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. ( 29380498 )
2018
3
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
4
HAVCR1 (CD365) and its mouse ortholog are functional hepatitis A virus (HAV) cellular receptors that mediate HAV infection. ( 29437974 )
2018
5
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
6
Seropositivity of Hepatitis A in Children Aged 7-14 Years in Diyarbakir Province Center. ( 29445079 )
2018
7
Protective efficacy of a bivalent live attenuated vaccine against duck hepatitis A virus types 1 and 3 in ducklings. ( 29408021 )
2018
8
Hepatitis A, cardiomyopathy, aplastic anemia, and acute liver failure: A devastating scenario. ( 29359844 )
2018
9
Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis- A Multinational, Prospective, Controlled, Randomized Trial. ( 29385313 )
2018
10
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. ( 29427580 )
2018
11
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
12
Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. ( 29324766 )
2018
13
Steroid therapy in children with fulminant hepatitis A. ( 29397017 )
2018
14
Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage. ( 29381561 )
2018
15
Experimental infection of Marmota monax with a novel hepatitis A virus. ( 29387970 )
2018
16
Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels. ( 29371712 )
2018
17
The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. ( 29398275 )
2018
18
Molecular genetic identification of isolates of the hepatitis A virus (HAV) from monkeys at Adler Primate Center. ( 29380396 )
2018
19
Hepatitis A vaccination coverage among adolescents (13-17a8^years) in the United States, 2008-2016. ( 29449100 )
2018
20
Duck hepatitis A virus structural proteins expressed in insect cells self-assemble into virus-like particles with strong immunogenicity in ducklings. ( 29426402 )
2018
21
Improved TaqMan real-time assays for detecting hepatitis A virus. ( 29409997 )
2018
22
Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A. ( 29440324 )
2018
23
Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. ( 28940673 )
2017
24
Course of hepatitis E infection in a patient with rheumatoid arthritis and autoimmune hepatitis: A case report. ( 29390558 )
2017
25
Prevalence of G6PD deficiency in Children with Hepatitis A. ( 28875002 )
2017
26
Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site. ( 28074040 )
2017
27
Elimination of representative contaminant candidate list viruses, coxsackievirus, echovirus, hepatitis A virus, and norovirus, from water by coagulation processes. ( 28011355 )
2017
28
The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited. ( 28884240 )
2017
29
Hepatitis A with Superadded Salmonella paratyphi A Infection Presenting with Exudative Pleural Effusion and Acalculous Cholecystitis. ( 28667735 )
2017
30
Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus. ( 28670260 )
2017
31
Granulomatous hepatitis: a rare primary manifestation of disseminated histoplasmosis in a renal transplant recipient. ( 28617878 )
2017
32
TIM1 (HAVCR1) Is Not Essential for Cellular Entry of Either Quasi-enveloped or Naked Hepatitis A Virions. ( 28874468 )
2017
33
Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm. ( 28926326 )
2017
34
Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. ( 29082266 )
2017
35
Acute-on-chronic hepatitis. A case report of autoimmune hepatitis/primary sclerosing cholangitis/ulcerative colitis overlap syndrome in a 15-year-old patient. ( 28856287 )
2017
36
Gutuo Jiejiu decoction improves survival of patients with severe alcoholic hepatitis: A retrospective cohort study. ( 28522913 )
2017
37
A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine. ( 28060048 )
2017
38
A large prolonged outbreak of hepatitis A associated with consumption of frozen berries, Italy, 2013-14. ( 28086079 )
2017
39
Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis. ( 28910270 )
2017
40
Physician Knowledge and Attitudes about Hepatitis A and Current Practices Regarding Hepatitis A Vaccination Delivery. ( 28089593 )
2017
41
Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study. ( 28834875 )
2017
42
Immune Thrombocytopenic Purpura and Hemolytic Anemia Secondary to Hepatitis A. ( 28875001 )
2017
43
Persistence of Antibody to Hepatitis A Virus 20 Years After Receipt of Hepatitis A Vaccine in Alaska. ( 28092416 )
2017
44
Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. ( 28919226 )
2017
45
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. ( 28887164 )
2017
46
A Cluster of Hepatitis A Viral Infection in HSE South. ( 28952677 )
2017
47
Acute hepatitis A infection after hepatitis A immunity in a HIV-positive individual. ( 28860200 )
2017
48
Development of a fast and efficient method for hepatitis A virus concentration from green onion. ( 28919035 )
2017
49
Fatal acute hepatic failure in a family infected with the hepatitis A virus subgenotype IB: A case report. ( 28858094 )
2017
50
Notes from the Field: Increase in Reported Hepatitis A Infections Among Men Who Have Sex with Men - New York City, January-August 2017. ( 28934181 )
2017

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 AFP ALB F2 F3 IFNA2 SERPINA1
2 cell surface GO:0009986 9.77 F3 HAVCR2 HSPA5 TGFB1 TNF
3 blood microparticle GO:0072562 9.56 ALB F2 SERPINC1 TGFB1
4 platelet alpha granule lumen GO:0031093 9.5 ALB SERPINA1 TGFB1
5 endoplasmic reticulum lumen GO:0005788 9.43 AFP ALB F2 HSPA5 SERPINA1 SERPINC1
6 extracellular space GO:0005615 9.32 AFP ALB F2 F3 GPT IFNA2
7 extracellular exosome GO:0070062 10.01 ALB F2 F3 GPT HAVCR2 HSPA5

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.87 F2 IFNA2 TGFB1 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.75 F2 TGFB1 TNF
3 inflammatory response GO:0006954 9.73 HAVCR2 IFNA2 TGFB1 TNF
4 positive regulation of protein kinase B signaling GO:0051897 9.69 F3 TGFB1 TNF
5 post-translational protein modification GO:0043687 9.67 AFP ALB SERPINA1 SERPINC1
6 negative regulation of gene expression GO:0010629 9.62 HAVCR2 IFNA2 TGFB1 TNF
7 negative regulation of interleukin-6 production GO:0032715 9.58 HAVCR2 TNF
8 platelet degranulation GO:0002576 9.58 ALB SERPINA1 TGFB1
9 positive regulation of protein localization to nucleus GO:1900182 9.56 F2 TGFB1
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.55 HAVCR2 TNF
11 cellular protein metabolic process GO:0044267 9.55 AFP ALB F2 SERPINA1 SERPINC1
12 positive regulation of collagen biosynthetic process GO:0032967 9.54 F2 TGFB1
13 positive regulation of protein complex assembly GO:0031334 9.52 TGFB1 TNF
14 regulation of blood coagulation GO:0030193 9.49 F2 SERPINC1
15 negative regulation of myoblast differentiation GO:0045662 9.48 TGFB1 TNF
16 positive regulation of chemokine production GO:0032722 9.46 HAVCR2 TNF
17 blood coagulation GO:0007596 9.35 F2 F3 IFNA2 SERPINA1 SERPINC1
18 positive regulation of mononuclear cell migration GO:0071677 9.26 TGFB1 TNF
19 hemostasis GO:0007599 8.92 F2 F3 SERPINA1 SERPINC1

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.92 F3 SERPINA1 SERPINC1 TNF

Sources for Hepatitis a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....